Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16405081 | 1.00 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNA7ADRA1AADRA2A | |
| SCHEMBL7666599 | 1.00 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNA7ADRA1AADRA2A | |
| Hydrochloric Acid SCHEMBL27828833 | 0.98 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNA7ADRA1AADRA2A | |
| Hydrochloric Acid SCHEMBL15169508 | 0.98 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNA7ADRA1AADRA2A | |
| Hydrochloric Acid SCHEMBL28603590 | 0.98 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNA7ADRA1AADRA2A | |
| SCHEMBL6173530 | 0.94 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNA7ADRA1AADRA2A | |
| Naphthalene SCHEMBL27966102 | 0.90 | ADRA1A (0.45) | CHRNB2CHRNA4CHRNA7ADRA1AADRA2A | |
| Acetic Acid SCHEMBL27758904 | 0.89 | CREBBP (0.38) | CHRNB2CHRNA4CHRNA7ADRA1AADRA2A | |
| SCHEMBL27651097 | 0.76 | ADRA1A (0.40) | ADRA1AADRA2AADRA1DADRA1BSMN1; SMN2 | |
| SCHEMBL1494449 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101558059-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2014-12-03 | — | — | CN | claimed |
| CN-102712628-B | Hepatitis c virus inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2014-10-15 | — | — | CN | claimed |
| CN-102712628-A | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2012-10-03 | — | — | CN | claimed |
| CN-101558059-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-10-14 | — | — | CN | claimed |
| WO-2021123785-A1 | DNA POLYMERASE THETA INHIBITORS | ARTIOS PHARMA LIMITED (GB) | 2021-06-24 | — | — | WO | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2900656-B1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-05-17 | — | — | EP | disclosed |
| CN-103819459-B | Anti-Viral Compounds | 艾伯维巴哈马有限公司 | 2017-05-17 | — | — | CN | disclosed |
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-05-11 | — | — | US | disclosed |
| EP-2379524-A1 | SEROTONIN 5-HT2B RECEPTOR INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-10-26 | — | — | EP | disclosed |
| EP-2337781-A2 | ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION | Abbott Laboratories (US) | 2011-06-29 | — | — | EP | disclosed |
| CN-101998952-A | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2011-03-30 | — | — | CN | disclosed |
| WO-2010120621-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010080357-A1 | SEROTONIN 5-HT2B RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
| CN-101558059-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-10-14 | — | — | CN | disclosed |
| CN-101534829-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-09-16 | — | — | CN | disclosed |
| CN-101528232-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-09-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | CHRNB2 4763/4885CHRNA4 4749/4885CHRNA7 4579/4885 |
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, PREP | CHRNB2 4884/4885CHRNA4 4875/4885CHRNA7 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.